

ForPatients

by Roche

Advanced Solid Tumors HER2-Positive Breast Cancer

A Phase 1 Trial of ZN-A-1041 Enteric Capsules or Combination in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Solid Tumors

Trial Status

Active, not recruiting

Trial Runs In

7 Countries

Trial Identifier

NCT05593094 ZN-A-1041-101-US,2023-508459-37-00 XO45189

The source of the below information is the publicly available website [ClinicalTrials.gov](https://clinicaltrials.gov). It has been summarised and edited into simpler language.

Trial Summary:

This will be a Phase 1, multicenter, open-label trial to evaluate the safety, tolerability, PK and efficacy of ZN-A-1041 as a monotherapy or in combination in participants with HER2-positive advanced solid tumors with or without brain metastases. The study will consist of three phases: Phase 1a (dose escalation with ZN-A-1041 monotherapy), Phase 1b (dose escalation with ZN-A-1041 combination therapy) and Phase 1c (dose expansion with ZN-A-1041 combination therapy).

Hoffmann-La Roche

Sponsor

Phase 1/Phase 2

Phase

NCT05593094 ZN-A-1041-101-US,2023-508459-37-00 XO45189

Trial Identifiers

Eligibility Criteria:

Gender

All

Age

>=18 Years

Healthy Volunteers

No